NEW YORK–(BUSINESS WIRE)–APx Acquisition Corp. I (“APx” or the “Company”), a special purpose acquisition company, announced today that the Company deposited into the trust account, established in connection with the […]

COLUMBUS, Ind.–(BUSINESS WIRE)–Cummins Inc. (NYSE: CMI) today announced that its Filtration business, Atmus Filtration Technologies, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission […]

GRT Board and Management Determined Listing of Common Shares Represents Best Available Path to Providing Liquidity to Shareholders and Maximizing Value Announces Several Strategic Actions Related to Proposed Listing EL […]

FORT WORTH, Texas–(BUSINESS WIRE)–As previously announced, in connection with its initial public offering (the “IPO”), TXO Energy Partners, L.P. (formerly known as MorningStar Partners, L.P., “TXO”) (NYSE: TXO) granted the […]

WASHINGTON–(BUSINESS WIRE)–Cava Group, Inc. (“CAVA”) announced today that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to […]

FORT WORTH, Texas–(BUSINESS WIRE)–MorningStar Partners, L.P., which will be renamed “TXO Energy Partners, L.P.” (“TXO”), announced today the pricing of its initial public offering of 5,000,000 common units representing limited […]

FORT WORTH, Texas–(BUSINESS WIRE)–MorningStar Partners, L.P., which will be renamed “TXO Energy Partners, L.P.” (“TXO”), announced today the launch of its initial public offering of 5,000,000 common units representing limited […]

A leader in precision care, focused on creating a world where healthcare has no limits Attractive financial profile supported by commitment to accelerating growth, margin expansion, and free cash flow […]

HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (“Coya” or the “Company”) (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells (“Tregs”), today announced the closing […]

HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (“Coya” or the “Company”) (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells (“Tregs”), today announced the pricing […]